EyePoint’s digital transformation strategy involves digitizing critical operational areas to support its clinical-stage biopharmaceutical development and manufacturing. This includes enhancing global clinical trial management, implementing advanced manufacturing controls, and strengthening regulatory compliance systems. EyePoint focuses on integrating technology to accelerate drug development and ensure product quality, particularly for its proprietary Durasert E™ technology and lead product candidate DURAVYU™.
This transformation creates significant dependencies on robust systems for data integrity, process automation, and regulatory adherence. Challenges arise from managing vast amounts of clinical data, ensuring manufacturing consistency, and maintaining strict compliance with global health regulations. This page will analyze EyePoint's key digital transformation initiatives, highlighting operational breakdowns and identifying opportunities for sellers.
Eyepoint Snapshot
Headquarters: Watertown, MA, United States
Number of employees: 201-500 employees
Public or private: Public
Business model: B2B
Website: http://www.eyepoint.bio
Eyepoint ICP and Buying Roles
EyePoint sells to biopharmaceutical companies developing and manufacturing complex therapeutic products.
- Companies managing global clinical trials and manufacturing operations.
Who drives buying decisions
-
Chief Medical Officer → Oversees clinical trial execution and data integrity.
-
Chief Manufacturing Officer → Leads manufacturing operations and supply chain management.
-
Chief Regulatory Officer → Ensures compliance with global health regulations.
-
Chief Scientific Officer → Directs research and development for drug delivery technologies.
Key Digital Transformation Initiatives at Eyepoint (At a Glance)
-
Digitalizing clinical data management for global trials.
-
Automating manufacturing processes in cGMP facilities.
-
Standardizing regulatory reporting and compliance workflows.
-
Integrating R&D platforms for drug delivery technology development.
-
Digitalizing supply chain visibility for global operations.
Where Eyepoint’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Clinical Trial Management Systems | Clinical data management: data capture systems do not standardize across global sites. | Chief Medical Officer, Senior Clinical Trial Manager | Unify data collection formats for all trial sites. |
| Clinical data management: patient enrollment tracking lacks real-time updates for site managers. | Chief Medical Officer, Associate Director, Clinical Scientist | Provide a centralized platform for live enrollment status. | |
| Clinical data management: trial data reconciliation requires manual merging from disparate sources. | Chief Medical Officer, Senior Clinical Trial Manager | Integrate varied data inputs into a single analysis system. | |
| Manufacturing Execution Systems | Automated manufacturing processes: production line equipment monitoring systems fail to detect anomalies in real time. | Chief Manufacturing Officer, Senior Validation Engineer | Deliver instant alerts for process deviations. |
| Automated manufacturing processes: quality control data recording does not integrate with batch release systems. | Chief Manufacturing Officer, Director Quality Operations | Connect quality tests directly to batch approval processes. | |
| Automated manufacturing processes: manufacturing process parameters deviate without automatic alerts. | Chief Manufacturing Officer, Senior Validation Engineer | Trigger immediate notifications for critical parameter shifts. | |
| Regulatory Information Management | Regulatory compliance reporting: FDA audit trail generation pulls data from disconnected systems. | Chief Regulatory Officer, Chief Legal Officer | Consolidate audit data from all sources into one view. |
| Regulatory compliance reporting: GxP documentation version control creates inconsistency across departments. | Chief Regulatory Officer, Director, Quality Compliance | Enforce single-source versioning for all GxP documents. | |
| Regulatory compliance reporting: regulatory submission packages require manual collation of disparate files. | Chief Regulatory Officer, Chief Legal Officer | Automate assembly of submission documents. | |
| R&D Data Management Platforms | Drug delivery technology development: drug formulation data silos prevent comprehensive analysis across studies. | Chief Scientific Officer, VP of Research and Development | Centralize research data for integrated analysis. |
| Drug delivery technology development: preclinical research data does not integrate with clinical development platforms. | Chief Scientific Officer, R&D Scientists | Link early-stage findings to later-stage trial data. | |
| Supply Chain Planning Software | Supply chain digitalization: raw material procurement systems lack real-time supplier inventory data. | Chief Manufacturing Officer, Supply Chain Director | Provide live inventory status from all suppliers. |
| Supply chain digitalization: clinical trial supply distribution creates delays due to manual tracking. | Chief Manufacturing Officer, Head of Logistics | Track shipments and deliveries in real time. | |
| Supply chain digitalization: inventory levels across manufacturing sites do not synchronize automatically. | Chief Manufacturing Officer, Supply Chain Director | Automate stock updates across all facilities. |
Identify when companies like Eyepoint are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this company’s digital transformation unique
Eyepoint's digital transformation uniquely centers on the dual challenges of rigorous biopharmaceutical research and highly regulated manufacturing for ophthalmic therapies. Their approach prioritizes the development of proprietary drug delivery systems like Durasert E™, demanding specialized R&D data integration and precision manufacturing controls. This focus on innovative, sustained-release products for serious retinal diseases creates distinct requirements for clinical trial management and regulatory compliance. The company’s growth in a niche therapeutic area necessitates highly tailored digital solutions, distinguishing it from broader pharmaceutical or medical device firms.
Eyepoint’s Digital Transformation: Operational Breakdown
DT Initiative 1: Clinical Trial Management Digitalization
What the company is doing
EyePoint manages global Phase 3 clinical trials for its lead product candidate, DURAVYU™. This involves overseeing patient enrollment, collecting vast amounts of clinical data, and performing complex statistical analyses across numerous international sites. The goal is to efficiently gather evidence for regulatory submissions and product approval.
Who owns this
-
Chief Medical Officer
-
Associate Director, Clinical Scientist
-
Senior Clinical Trial Manager
Where It Fails
-
Clinical data capture systems do not standardize across global sites.
-
Patient enrollment tracking lacks real-time updates for site managers.
-
Trial data reconciliation requires manual merging from disparate sources.
-
Safety event reporting systems delay submission to regulatory bodies.
Talk track
Noticed EyePoint manages multiple global Phase 3 clinical trials for new therapies. Been looking at how some biopharma companies are standardizing data capture across all sites instead of manually reconciling disparate sources, can share what’s working if useful.
DT Initiative 2: Advanced Manufacturing Facility Implementation
What the company is doing
EyePoint operates a cGMP commercial manufacturing facility in Northbridge, Massachusetts. This facility supports the global production of its ophthalmic products, meeting stringent U.S. FDA and European Medicines Agency standards. It includes process engineering and quality control for innovative drug delivery systems.
Who owns this
-
Chief Manufacturing Officer
-
Senior Validation Engineer
-
Director Quality Operations
Where It Fails
-
Production line equipment monitoring systems fail to detect anomalies in real time.
-
Quality control data recording does not integrate with batch release systems.
-
Manufacturing process parameters deviate without automatic alerts.
-
Preventive maintenance scheduling for machinery relies on manual tracking.
Talk track
Saw EyePoint recently operationalized its cGMP manufacturing facility in Northbridge. Been looking at how some biopharma manufacturers are preventing production inconsistencies through real-time equipment monitoring instead of post-production audits, happy to share what we’re seeing.
DT Initiative 3: Regulatory Compliance System Enhancement
What the company is doing
EyePoint maintains a robust regulatory compliance program adhering to strict FDA and EMA guidelines for drug development and manufacturing. This includes managing comprehensive audit trails, GxP documentation, and ensuring timely submissions for product approvals. A Chief Regulatory Officer oversees these critical functions.
Who owns this
-
Chief Regulatory Officer
-
Chief Legal Officer
-
Director, Quality Compliance
Where It Fails
-
FDA audit trail generation pulls data from disconnected systems.
-
GxP documentation version control creates inconsistency across departments.
-
Regulatory submission packages require manual collation of disparate files.
-
Deviation management workflows do not trigger automatic investigations.
Talk track
Looks like EyePoint maintains a robust regulatory compliance program for its biopharmaceutical operations. Been seeing biopharma teams automate GxP document control instead of relying on manual version tracking, can share what’s working if useful.
DT Initiative 4: Proprietary Drug Delivery Technology Development
What the company is doing
EyePoint continuously develops and refines its Durasert E™ technology for sustained intraocular drug delivery. This involves extensive research and development, preclinical studies, and formulation optimization for novel therapeutic candidates like DURAVYU™. The process requires robust data management for scientific discovery and intellectual property protection.
Who owns this
-
Chief Scientific Officer
-
R&D Scientists
-
VP of Research and Development
Where It Fails
-
Drug formulation data silos prevent comprehensive analysis across studies.
-
Preclinical research data does not integrate with clinical development platforms.
-
Intellectual property tracking systems miss new patent opportunities.
-
Research material inventory management relies on manual updates.
Talk track
Came across EyePoint's ongoing development of its Durasert E™ technology for sustained drug delivery. Been looking at how some biopharma R&D teams are unifying research data for comprehensive analysis instead of working with disconnected silos, happy to share what we’re seeing.
DT Initiative 5: Supply Chain Digitalization for Global Operations
What the company is doing
EyePoint manages a complex global supply chain for clinical trials and its manufacturing operations. This includes sourcing specialized raw materials, distributing clinical trial supplies, and ensuring timely delivery of commercial products. The company focuses on maintaining the integrity of temperature-sensitive biological materials.
Who owns this
-
Chief Manufacturing Officer
-
Supply Chain Director
-
Head of Logistics
Where It Fails
-
Raw material procurement systems lack real-time supplier inventory data.
-
Clinical trial supply distribution creates delays due to manual tracking.
-
Inventory levels across manufacturing sites do not synchronize automatically.
-
Logistics routing for temperature-sensitive materials does not adjust for disruptions.
Talk track
Noticed EyePoint manages a complex global supply chain for its biopharmaceutical products. Been looking at how some biopharma companies are automating real-time inventory synchronization across all facilities instead of relying on periodic manual checks, can share what’s working if useful.
Who Should Target Eyepoint Right Now
This account is relevant for:
-
Clinical trial management and data integration platforms
-
Manufacturing execution systems (MES) for biopharma
-
Regulatory information management (RIM) solutions
-
GxP document and quality management systems
-
R&D data and laboratory information management systems (LIMS)
-
Biopharma supply chain planning and visibility platforms
Not a fit for:
-
Generic HR and payroll software
-
Standard e-commerce platforms
-
General purpose marketing automation tools
When Eyepoint Is Worth Prioritizing
Prioritize if:
-
You sell solutions for standardizing clinical data capture across global sites.
-
You sell systems for real-time equipment monitoring in cGMP manufacturing.
-
You sell platforms for automating GxP documentation version control.
-
You sell integrated R&D data management systems for drug formulation.
-
You sell solutions for real-time inventory synchronization across global supply chain facilities.
Deprioritize if:
-
Your solution does not address any of the breakdowns above.
-
Your product is limited to basic functionality without specialized biopharma capabilities.
-
Your offering is not built for highly regulated or global operational environments.
Who Can Sell to Eyepoint Right Now
Clinical Trial Technology Providers
Medidata Solutions - This company provides cloud-based solutions for clinical research, including electronic data capture (EDC) and clinical trial management systems (CTMS).
Why they are relevant: EyePoint’s global Phase 3 clinical trials struggle with inconsistent data capture and manual reconciliation across sites. Medidata can standardize data collection processes, streamline patient enrollment tracking, and integrate disparate data sources to improve the efficiency and accuracy of clinical trial management.
Veeva Systems - This company offers cloud software for the global life sciences industry, including clinical operations, data management, and regulatory solutions.
Why they are relevant: EyePoint faces challenges with patient enrollment visibility and efficient data flow across its multi-site trials. Veeva’s CTMS and EDC platforms can provide real-time dashboards for enrollment status, automate data validation, and connect clinical data directly into a unified system for faster insights.
Biopharma Manufacturing & Quality Solutions
Sparta Systems (a Honeywell Company) - This company provides enterprise quality management software (EQMS) for highly regulated industries, including pharmaceutical manufacturing.
Why they are relevant: EyePoint’s cGMP facility requires stringent quality control, but its data recording does not integrate with batch release systems. Sparta Systems can enforce closed-loop quality processes, linking manufacturing execution data directly to quality events and batch disposition to prevent inconsistencies.
Werum IT Solutions (part of Körber AG) - This company delivers Manufacturing Execution Systems (MES) specifically designed for the pharmaceutical and biotech industries.
Why they are relevant: EyePoint’s production lines need robust monitoring, but existing systems fail to detect anomalies in real time. Werum IT Solutions’ MES can provide granular control over manufacturing processes, trigger immediate alerts for parameter deviations, and integrate equipment monitoring with quality data to prevent production inconsistencies.
Regulatory & Compliance Software
MasterControl - This company offers quality management system (QMS) and manufacturing execution system (MES) software solutions for regulated industries.
Why they are relevant: EyePoint’s GxP documentation suffers from inconsistent version control, leading to compliance risks. MasterControl can centralize all GxP documents, enforce automated version control, and provide an immutable audit trail, ensuring regulatory adherence and simplifying FDA audit generation.
ARIS Global - This company provides pharmacovigilance, clinical, regulatory, and quality solutions for life sciences.
Why they are relevant: EyePoint’s regulatory submission process involves manual collation of disparate files, increasing the risk of delays. ARIS Global’s regulatory information management (RIM) platform can automate the assembly of submission packages, manage regulatory deadlines, and streamline communication with health authorities.
R&D and Lab Informatics
Thermo Fisher Scientific (SampleManager LIMS) - This company offers Laboratory Information Management Systems (LIMS) for managing lab data and workflows across scientific research.
Why they are relevant: EyePoint’s drug formulation R&D involves data silos that prevent comprehensive analysis across studies. SampleManager LIMS can centralize all research data, track material inventory automatically, and integrate preclinical data with other development platforms, improving data accessibility and integrity.
Dotmatics - This company provides R&D software solutions that connect science, data, and decision-making across the research lifecycle.
Why they are relevant: EyePoint struggles with integrating preclinical research data into clinical development platforms, slowing the drug development process. Dotmatics can create a unified environment for scientific data, enabling seamless data flow from early discovery to clinical trials and facilitating comprehensive analysis across the entire R&D pipeline.
Final Take
EyePoint scales clinical trials and cGMP manufacturing for its innovative ophthalmic therapeutics, creating dependencies on robust data and process controls. Breakdowns are visible in fragmented clinical data, inconsistent manufacturing quality, and manual regulatory reporting. This account is a strong fit for sellers offering specialized biopharma solutions that enforce data standardization, automate critical workflows, and integrate systems across R&D, clinical, manufacturing, and compliance operations.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.